(Q46505727)

22 December 2017

title

Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes (English)

1 reference

22 December 2017

0 references

Hee Young Kang

1

1 reference

22 December 2017

Tae Jun Park

series ordinal

2

1 reference

22 December 2017

Sun Hee Jin

series ordinal

3

1 reference

22 December 2017

language of work or name

English

0 references

publication date

3 July 2008

1 reference

22 December 2017

Journal of Investigative Dermatology

published in

1 reference

22 December 2017

volume

129

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

243-246

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/jid.2008.184

exact match

0 references

cites work

Human melanocytes express functional Toll-like receptor 4.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Imiquimod: a cytokine inducer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Melanocytes are potential immunocompetent cells: evidence from recognition of immunological characteristics of cultured human melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Imiquimod as an antiaging agent

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Evidence for an autoimmune pathogenesis of vitiligo

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Immunomodulatory and pharmacologic properties of imiquimod

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Melanin pigmentation in mammalian skin and its hormonal regulation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Imiquimod-induced vitiligo in a patient with genital warts

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.184

7 January 2021

Identifiers

DOI

10.1038/JID.2008.184

1 reference

22 December 2017

1 reference

22 December 2017